Sugi Predict

Sugi Predict / Compounds / SCHEMBL400316

SCHEMBL400316

SCHEMBL400316

Cc1ccc(NC(=O)Nc2cc(CN3CCN4[C@H](C3)CN(C)S4(=O)=O)ccc2F)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 3/20 0.38
▸ MAPK10 P53779 3/20 0.38
▸ CHEK1 O14757 1/20 0.38
▸ KCNQ3 O43525 1/20 0.37
▸ KCNQ2 O43526 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HTR2C P28335 1/20 0.37
▸ MAPK9 P45984 2/20 0.36
▸ MTOR P42345 2/20 0.36
▸ KIT P10721 2/20 0.36
▸ ABL1 P00519 2/20 0.36
▸ BCR P11274 1/20 0.36
▸ CCR3 P51677 1/20 0.36
▸ ROCK2 O75116 2/20 0.36
▸ LIMK1 P53667 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ GALR3 O60755 1/20 0.36
▸ KDR P35968 3/20 0.35
▸ TEK Q02763 2/20 0.35
▸ PIK3CA P42336 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL398396 1.00 MAPK8 (0.38) MAPK8MAPK10CHEK1KCNQ3KCNQ2
SCHEMBL23573794 0.89 AXL (0.37) KITABL1BCRROCK2KDR
SCHEMBL23573757 0.89 AXL (0.37) KITABL1BCRROCK2KDR
SCHEMBL401842 0.87 PLK4 (0.38) MAPK8MAPK10HTR2AHTR2CCCR3
SCHEMBL400317 0.87 PLK4 (0.38) MAPK8MAPK10HTR2AHTR2CCCR3
SCHEMBL397586 0.82 LTA4H (0.42) MAPK8MAPK10KCNQ3KCNQ2HTR2A
SCHEMBL401672 0.82 LTA4H (0.42) MAPK8MAPK10KCNQ3KCNQ2HTR2A
SCHEMBL402276 0.81 MEN1 (0.46) MAPK8MAPK10KCNQ3KCNQ2MAPK9
SCHEMBL398928 0.80 CCR3 (0.46) CCR3RAB9AGALR3
SCHEMBL402434 0.80 GALR3 (0.45) MAPK8MAPK10KCNQ3KCNQ2CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US claimed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US claimed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US claimed
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2015-01-01 — — US claimed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US claimed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US claimed
US-12264133-B2 Compounds, compositions and methods CYTOKINETICS, INCORPORATED (US) 2025-04-01 — — US disclosed
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2022-06-16 — — US disclosed
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2021-07-01 — — US disclosed
US-10975034-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2021-04-13 — — US disclosed
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2019-11-21 — — US disclosed
US-10385023-B2 Compounds, compositions and methods CYTOKINETICS, INC. (US) 2019-08-20 — — US disclosed
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED 2018-10-25 — — US disclosed
US-20090099198-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. 2009-04-16 — — US disclosed
US-7507735-B2 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INC. (US) 2009-03-24 — — US disclosed
US-20090036447-A1 Compounds, Compositions and Methods CYTOKINETICS, INC. (US) 2009-02-05 — — US disclosed
US-20070208000-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-09-06 — — US disclosed
US-20070197505-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-08-23 — — US disclosed
US-20070161617-A1 Certain chemical entities, compositions and methods CYTOKINETICS, INC. 2007-07-12 — — US disclosed
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate CYTOKINETICS, INCORPORATED 2006-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161617-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MAPK8 3317/4885MAPK10 2458/4885CHEK1 1935/4885
US-20060014761-A1 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 4-[(3-fluoro-5-{[(6-methyl(3-pyridyl))amino]carbonylamino}-phenyl)methyl]piperazinecarboxylate TNNI3, MYLK2, TNNT2 MAPK8 2821/4885MAPK10 1989/4885CHEK1 2918/4885
US-10385023-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-20220185779-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-12264133-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-20090099198-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-20190352267-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-20070208000-A1 Certain chemical entities, compositions and methods TNNI3, TNNT2, MYLK2 MAPK8 3317/4885MAPK10 2458/4885CHEK1 1935/4885
US-20070197505-A1 Certain chemical entities, compositions and methods TNNC1, TNNI3, TNNT2 MAPK8 3594/4885MAPK10 2706/4885CHEK1 358/4885
US-20150005296-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-10975034-B2 Compounds, compositions and methods TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-20090036447-A1 Compounds, Compositions and Methods TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-20180305316-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885
US-20210198203-A1 COMPOUNDS, COMPOSITIONS AND METHODS TNNI3, TNNC1, TNNT2 MAPK8 3460/4885MAPK10 2521/4885CHEK1 2194/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.